IDNAvsIGSB
iShares Genomics Immunology and Healthcare ETF against iShares 1-5 Year Investment Grade Corporate Bond ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| IDNA | IGSB | |
|---|---|---|
| Expense ratio | 0.47% | 0.040% |
| Assets | $219M | $23.4B |
| Net flow, 1 month | +$7M | +$527M |
| Net flow, 1 year | +$36M | +$1.7B |
| Return, YTD | +55.4% | -1.3% |
| Return, 1 year | +80.7% | -1.2% |
| Avg daily volume | 46K | 2.7M |
| Holdings | 63 | 3892 |
| Listed | Jun 10, 2019 | Jan 4, 2007 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS